WO2010069141A1 - 具有润滑层结构的双层渗透泵控释片及其制备方法 - Google Patents

具有润滑层结构的双层渗透泵控释片及其制备方法 Download PDF

Info

Publication number
WO2010069141A1
WO2010069141A1 PCT/CN2009/001473 CN2009001473W WO2010069141A1 WO 2010069141 A1 WO2010069141 A1 WO 2010069141A1 CN 2009001473 W CN2009001473 W CN 2009001473W WO 2010069141 A1 WO2010069141 A1 WO 2010069141A1
Authority
WO
WIPO (PCT)
Prior art keywords
layer
controlled release
double
osmotic pump
drug
Prior art date
Application number
PCT/CN2009/001473
Other languages
English (en)
French (fr)
Inventor
蒋海松
王锦刚
Original Assignee
北京科信必成医药科技发展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京科信必成医药科技发展有限公司 filed Critical 北京科信必成医药科技发展有限公司
Priority to CN2009801509213A priority Critical patent/CN102264356A/zh
Priority to JP2011541060A priority patent/JP2012512187A/ja
Priority to US13/140,288 priority patent/US20120015028A1/en
Priority to EP09832823.0A priority patent/EP2380562A4/en
Publication of WO2010069141A1 publication Critical patent/WO2010069141A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Definitions

  • the invention relates to the field of pharmaceutical preparations, in particular to a double-layer osmotic pump controlled release tablet preparation, and to a preparation method of the controlled release tablet. Background technique
  • Osmotic pump controlled release tablets are typical Class 0 release controlled release formulations.
  • the layer osmotic pump solves the technical problem that the poorly soluble drug is made into the osmotic pump controlled release sheet.
  • the problem that the drug cannot be completely released often occurs.
  • the basic requirements of the Chinese Pharmacopoeia for controlled release preparations stipulate that the release platform of sustained release preparations should reach more than 90% of the release. At present, many double-layer osmotic pumps have failed to meet this requirement. At the same time, due to the incomplete release of drugs, the therapeutic effects and bioavailability of such drugs are seriously affected.
  • PEO polyoxyethylene
  • the side wall of the controlled release layer of the osmotic pump controlled release sheet and the non-Newtonian fluid formed by the drug-containing layer are very With a large shear force, the drug layer near the side wall of the semipermeable membrane moves at a speed of almost zero when propelled by the propelling layer, forming a drug release dead angle, which causes the drug to be completely pushed out by the push layer, and the drug cannot be completely released.
  • the low bioavailability of the drug has seriously affected the therapeutic effect of the drug.
  • the primary object of the present invention is to prepare a two-layer osmotic pump controlled release tablet which can release the drug completely, and improve the release effect of the conventional two-layer osmotic pump controlled release tablet.
  • Another object of the present invention is to provide the double layer penetration. Preparation method of pump controlled release tablets.
  • a double-layer osmotic pump controlled release tablet comprising: a double-layer core with a drug, a controlled release layer outside the core, and a release hole on the controlled release layer, having lubrication between the core and the controlled release layer Layer structure.
  • the drug-containing double-layer core, the controlled release layer and the drug release hole described in the present invention may be conventional, for example, the drug-containing double-layer core is composed of a drug-containing layer and a push layer; On the controlled release layer on one side of the drug layer.
  • the drug-containing layer and the push layer described in the present invention may be conventional, and materials for preparing a drug-containing layer and a push layer which are commonly used in the field of controlled release tablets of osmotic pumps are used.
  • the material of the push layer comprises a material that swells with water to push the drug layer out of the release orifice of the osmotic pump controlled release sheet.
  • the material of the push layer comprises polyethylene oxide ( ⁇ .).
  • the material of the push layer further comprises cellulose, preferably hydroxypropyl methylcellulose.
  • the drug-containing material comprises povidone.
  • the drug-containing layer material also includes cellulose, preferably hydroxypropyl methylcellulose.
  • the high substituted hydroxypropylcellulose has a viscosity of from 2.4 to 120 mPa-s, preferably from 12 to 80 mPa's.
  • the viscosity of the low viscosity hydroxypropyl methylcellulose is 5 ⁇
  • the medicated layer comprises a drug and povidone.
  • the drug-containing layer comprises a drug, povidone, and cellulose, preferably hydroxypropylmethylcellulose.
  • the propulsion layer comprises polyethylene oxide.
  • the pusher layer comprises polyethylene oxide and cellulose, preferably hydroxypropyl methylcellulose.
  • the material of the lubricating layer is selected from the group consisting of high-substituted hydroxypropylcellulose or low-viscosity hydroxypropyl fluorenyl ruthenium; and the weight is 0.5% to 6% by weight of the double-layer core.
  • the main material of the controlled release layer is cellulose acetate; the weight is 18% ⁇ 24% of the weight of the core layer.
  • the release orifice has a diameter between 0.4 and 1.2 mm.
  • the invention adds a lubricating layer between the core and the controlled release layer.
  • the lubricating layer can be quickly Hydration, into a liquid gel with good fluidity and lubrication effect, forming a lubricating layer between the core and the controlled release layer, reducing the medicated layer and the controlled release layer of the double layer.
  • the shear force between the drug-containing layers can be smoothly pushed out by the push layer, and the drug release rate is close to 100% within 24 hours.
  • the preparation method of the double-layer osmotic pump controlled release tablet of the invention is as follows: the drug and the auxiliary material are made into a core layer containing the drug, and a lubricating layer is wrapped outside the core, and then the outer layer of the lubricating layer is controlled and released. The layer is then perforated on the side of the drug-containing layer to form a double-layer osmotic pump controlled release tablet. Depending on the needs of the production, it is also possible to selectively apply a conventional film coat to the outer layer of the controlled release layer. The preparation process of the lubricating layer, the controlled release layer and the film coating can be carried out using a high-efficiency coating machine.
  • a double-layer core containing a drug is prepared: a material containing a drug layer and a material of a push layer are taken, and a double-layer core is formed by a double-layer tablet machine.
  • Preparation of lubricating layer coating liquid Take appropriate amount of lubricating layer material into water or ethanol or any proportion of water-ethanol solution, soak, stir to dissolve.
  • the lubricating layer material is selected from the group consisting of highly substituted hydroxypropyl cellulose or low viscosity hydroxypropyl methylcellulose. Since hydroxypropylcellulose and hydroxypropylmethylcellulose are soluble in water and soluble in ethanol, they can be dissolved in any proportion of water-ethanol solution.
  • the concentration of the lubricating layer coating liquid is controlled between 2% and 20%.
  • the solvent with a high water content has a higher coating temperature at the time of coating, while the solution with a higher ethanol content has a lower temperature, but the cost is higher and there is a safety hazard. Therefore, drugs that are unstable to high temperature cannot be used as coating liquids with high water content, and coating liquids containing higher ethanol can be used, and even ethanol can be used as a solvent; for drugs that are not sensitive to temperature, solvents containing more water can be used. You can even use a solvent system that is completely water.
  • Packing layer Take the double layer in the high-efficiency coating machine, coat with the lubricating layer coating liquid, and increase the weight of the lubricating layer coating (that is, the weight of the lubricating layer relative to the weight of the core of the layer) Control is within 0.5% ⁇ 6%.
  • the air inlet temperature of the coating machine is controlled between 40 and 65 °C.
  • Controlled release layer Take the double-layer sheet with the lubricating layer in the high-efficiency coating machine, coat it with the controlled release layer coating solution, and increase the weight of the controlled release layer (ie the weight of the controlled release layer relative to the double Layer core weight The percentage of the amount is 18% ⁇ 24%, and the inlet air temperature of the coating machine is controlled between 15 ⁇ 35 °C.
  • Controlled release layer aging The two-layer sheet with the controlled release layer is taken and dried in a drying device.
  • the drying temperature is controlled between 35 °C and 60 °C, and the residual amount of acetone is below 0.05%.
  • Film-coated garments can be optionally applied to the outside of a perforated two-layer osmotic pump controlled release tablet using conventional tablet coating techniques.
  • the double-layer osmotic pump controlled release sheet of the invention has a lubricating layer added on the basis of the traditional double-layer osmotic pump controlled release sheet, and the lubricating layer is composed of a material which is easy to be hydrated, and the lubricating layer is hydrated to form a gel film having lubricating effect. , has a good lubrication.
  • the propelling layer absorbs water and expands, pushing the drug layer upwards, due to the lubricating effect of the lubricating layer, the drug layer can be moved as a whole without dead angles, and the final drug layer is completely pushed out, and the drug is completely released.
  • the lubricating layer is composed of high-substituted hydroxypropylcellulose or low-viscosity hydroxypropylmethylcellulose, and the entire double-layer core can be coated with a lubricating layer by a conventional coating method, and the process is simple and easy to operate, but the drug is The release effect is greatly improved, and at the same time, the coating process of the controlled release layer is not affected, and the big problem is solved by the simplest method.
  • the two-layer osmotic pump controlled release tablet of the present invention is a nifedipine two-layer osmotic pump controlled release tablet, and the drug in the two-layer tablet core is nifedipine.
  • FIG. 1 is a schematic structural view of a two-layer osmotic pump controlled release sheet having a lubricating layer structure of the present invention, wherein: 1-drug layer; 2-pushing layer; 3-lubricating layer; 4-controlled release layer; 5 --release hole. 2 is a graph showing the release effect of Example 1.
  • Figure 3 shows the effect of the amount of lubricant on the release
  • Figure 4 shows the effect of controlled release membrane weight gain on release.
  • Example 1 Nifedipine osmotic pump controlled release sheet with lubricating layer structure.
  • the preparation method is as follows.
  • Micronization of nifedipine raw material Take nifedipine raw material for micronization treatment, and obtain micronized raw material medicine with particle size below ⁇ ;
  • the pressed double-layer sheet is coated on the high-efficiency coating machine with a lubricating layer, the coating process controls the film bed temperature to be 45 ⁇ 2° C., and the lubricating layer has a weight gain of 1%;
  • Acetic acid cellulose, polyethylene glycol 1500, dibutyl sebacate are sequentially added to acetone, and the mixture is stirred to disperse. After all the solid matter is swollen, stirring is continued to dissolve, and it is reserved;
  • Controlled release layer The coated material of the coated garment is packaged on the high-efficiency coating machine to control the release film. The coating process does not need to heat the material bed, and the weight of the control coating is calculated according to the double-layer core. % ( w/w );
  • Controlled release layer aging 'The sheet containing the controlled release layer was placed in an oven at 40 ⁇ 45 °C and aged for 16 hours.
  • Laser drilling Remove the aged tablets and use a laser punch to make a release hole in the center of the drug-containing layer with a pore size of 700 ⁇ m.
  • the structure of the nifedipine osmotic pump controlled release sheet having the lubricating layer structure is as shown in Fig. 1.
  • the two layers are composed of the drug-containing layer 1 and the push layer 2, and the lubricating layer 3 is sequentially arranged outside the double-layer core.
  • the controlled release layer 4 has a drug releasing hole 5 on the side of the drug-containing layer of the controlled release sheet.
  • the first method for the determination of the release rate is determined by the second method of dissolution.
  • the release was determined by HPLC at 100 rpm.
  • the chromatographic conditions were: C18 was the stationary phase and the mobile phase was: acetonitrile-methanol-water (20:30:50).
  • the measured release, the result is more than 90% release over 24 hours, in line with the general provisions of the Chinese Pharmacopoeia on controlled release formulations.
  • the release curve is shown in Figure 2. Time (h) 0 4 8 12 16 24 Release 0.0% 17.3% 40.1% 62.3% 75.8% 96.0%
  • Example oo 2 Effect of the amount of lubricating layer on release
  • nifedipine osmotic pump controlled release tablets were prepared according to the same materials, dosages and operations as in Example 1, except that the weight gain of the lubricating layer was 0.5% and 6%, respectively, and the influence of the amount of the lubricating layer on the release was evaluated.
  • the weight gain of the lubricating layer was 0.5% and 6%, respectively, and the influence of the amount of the lubricating layer on the release was evaluated.
  • the 24-hour release is greater than 90%.
  • the measured release profile is shown in Figure 3.
  • the nifedipine osmotic pump controlled release tablets were prepared according to the same materials, dosages and operations as in Example 1. The difference was that the controlled release film coating weight gain was 18% and 24%, respectively, and the release was in accordance with the Chinese Pharmacopoeia.
  • the general provisions for controlled release formulations have a 24-hour release greater than 90%. The measurement results are as follows. The release curve is shown in Figure 4.
  • a two-layer sheet was prepared in accordance with the procedure of Example 1, and a lubricating layer coating liquid of two different solvents was prepared in accordance with the following formulation.
  • Lubricating layer 1 formula:
  • Preparation method Take 5 g of hydroxypropyl methylcellulose, add 75 g of ethanol, stir to dissolve, and set aside;
  • Packing layer Take the pressed double layer into two parts in a high-efficiency coating machine and apply it in several parts. ⁇ once the lubrication layer 1 , the second lubrication layer 2 , the coating process control bed temperature is 45 ⁇ 2 ° C, the weight gain of the lubrication layer is about 2%;
  • Example 2 Subsequent operations were carried out in accordance with the preparation method of Example 1.
  • the weight gain of the controlled release layer was 21.3% and 22.1%, respectively.
  • the release rate was determined according to the method of Example 1.
  • the release of the nifedipine osmotic pump controlled release tablets prepared by the solvent of the two different lubricating layers was in accordance with the Chinese Pharmacopoeia.
  • the general rule of preparation is that the 24-hour release is greater than 90%.
  • the measurement results are as follows. The release curve is shown in Figure 5.
  • the osmotic pump controlled release tablets with smooth release can be prepared by using water or ethanol as the solvent of the lubricating layer coating solution. There is no significant difference in the release of the two.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

具有润滑层结构的双层渗透泵控释片及其制备方法 技术领域
本发明涉及药物制剂领域, 具体涉及双层渗透泵控释片制剂, 并 涉及该控释片的制备方法。 背景技术
渗透泵控释片是典型的 0 级释放的控释制剂。 1974 年 Theeuwes 发明了单室渗透泵, 使渗透泵简化为普通包衣片, 并在片剂的一侧打 孔的简单形式。 至此渗透泵成为临床上可以应用的一种剂型,由此产生 了一系列的单室渗透泵控释片剂型。 80年代至今对渗透泵的改进研究 工作一直没有停止, 为了满足将难溶性药物制成渗透泵或将水溶性较 好但自身不能产生渗透压的药物制成渗透泵的要求, 出现了单室欢层 渗透泵, 解决了难溶性药物制成渗透泵控释片的技术问题。 但双层渗 透泵控释片技术在应用的过程经常出现药物不能释放完全的问题。 中 国药典关于緩控释制剂的基本要求中规定, 緩释制剂的释放平台应当 达到 90%以上的释放量, 目前很多双层渗透泵控释不能达到这一要求。 同时由于药物不能完全释放严重影响了此类药物的治疗效果和生物利 用度。
产生药物不能完全释放的原因在于, 聚氧化乙烯(PEO )是制备双 层渗透泵控释片不可缺少的材料, 该材料遇水膨胀, 进一步水化后形 成非牛顿流体, 在推进层的推动下夹带药物从渗透泵控释片的释药孔 排出, 恒速释放药物。 由于含有聚氧化乙烯的药物层在水化后形成非 牛顿流体, 根据非牛顿流体的基本性质可知, 渗透泵控释片的控释层 侧壁与含药层形成的非牛顿流体之间具有很大的剪切力, 靠近半透膜 侧壁的药物层在受到推进层的推进作用时移动速度几乎为 0 ,形成药物 释放死角, 导致这部分药物不能被推进层完全推出, 药物不能完全释 放, 药物的生物利用度偏低, 严重影响了药物的治疗效果。 为了解决 双层渗透泵控释片存在的问题, 开发了具有润滑层结构的双层渗透泵 控释片。 发明内容 本发明的首要目的是制备出一种可以将药物释放完全的双层渗透 泵控释片, 改进常规双层渗透泵控释片的释放效果; .本发明的另一个 目的是提供该双层渗透泵控释片的制备方法。
本发明为实现其发明 ϋ的所釆用的技术方案是:
一种双层渗透泵控释片, 包括^ ^有药物的双层片片芯, 片芯外的 控释层和控释层上的释药孔, 在片芯和控释层之间具有润滑层结构。
本发明中所述的含有药物的双层片芯、 控释层和释药孔可以是常 规的, 如, 含有药物的双层片芯由含药层和推进层组成; 释药孔设置 在含药层一侧的控释层上。
本发明中所述的含药层和推进层可以是常规的, 并且使用渗透泵 控释片领域中常用的用于制备含药层和推进层的材料。 众所周知, 推 进层的材料包括遇水膨胀以推动药物层从渗透泵控释片的释药孔排 ¾ 的材料。 在一个实施方案中, 推进层的材料包括聚氧化乙烯 (ΡΕΟ. ) 。 在另一个实施方案中, 除了聚氧化乙烯以外, 推进层的材料还包括纤 维素, 优选羟丙基甲基纤维素。 在一个实施方案中, 含药层的材料包 括聚维酮。 在另一个实施方案中, 除了聚维酮以外, 含药层的材料还 包括纤维素, 优选羟丙基甲基纤维素。
在一个实施方案中,·所述高取代羟丙基纤维素的粘度为 2.4 ~ 120 mPa-s , 优选 12〜 80mPa's。
在一个实施方案中, 所述低粘度羟丙基甲基纤维素的粘度为 5 ~
100mPa-s , 优选 5 - 50mPa-s。
在一个实施方案中, 所述含药层包括药物和聚维酮。 在一个实施 方案中, 所述含药层包括药物、 聚维酮和纤维素, 优选羟丙基甲基纤 维素。
在一个实施方案中, 所述推进层包括聚氧化乙烯。 在一个实施方 案中, 所述推进层包括聚氧化乙烯和纤维素, 优选羟丙基甲基纤维素。
在本发明优选的技术方案中, 润滑层的材料选自高取代羟丙基纤 维素或低粘度羟丙基曱基歼维素; 重量是双层片片芯重量的 0.5% ~ 6%。控释层的主要材料为醋酸纤维素;重量是默层片片芯重量的 18% ~ 24%。 所述释药孔的直径在 0.4~1.2mm之间。
本发明在片芯与控释层之间增加了润滑层, 患者服用该渗透泵控 释片时, 消化道内的水通过控释层, 遇到润滑层时, 润滑层可以快速 水化, 变成具有良好流动性和润滑效果的液体凝胶, 在片芯与控释层 之间形成了一层具有润滑作用的润滑层, 减少了双层片的含药层与控 释层之间的剪切力, 使含药层的药物可以被推进层顺利整体推出, 24 小时内药物的释放率接近 100%。
本发明的双层渗透泵控释片的制备方法是: 将药物与辅料制成含 有药物的默层片片芯, 在片芯外先包裹一层润滑层, 再在润滑层的外 面包控释层, 然后在含药层一侧打孔, 制成双层渗透泵控释片。 根据 生产的需要, 还可以选择性地在控释层的外面包普通的薄膜衣。 润滑 层、 控释层和薄膜衣的制备工艺均可采用高效包衣机完成。
上述双层渗透泵控释片的制备方法的具体步骤如下:
( 1 )制备含有药物的双层片芯:取含药层的物料和推进层的物料, 用双层压片机制成双层片芯。
( 2 ) 制备润滑层包衣液: 取润滑层材料适量加入到水或乙醇或任 意比例的水一乙醇溶液中, 浸泡, 搅拌使溶解。 润滑层材料选自高取 代羟丙基纤维素或低粘度羟丙基甲基纤维素。 由于羟丙基纤维素和羟 丙基甲基纤维素即可以溶于水, 又可以溶于乙醇, 因此可以用任意比 例的水——乙醇溶液溶解。润滑层包衣液的浓度控制在 2% ~ 20%之间。 含水高的溶剂在包衣时的包衣温度较高, 而含乙醇较高的溶液包衣的 温度较低, 但成本较高, 同时有安全性隐患。 因此, 对高温不稳定的 药物不能用含水高的包衣液, 可以釆用含乙醇较高的包衣液, 甚至可 以采用乙醇为溶剂; 对温度不敏感的药物, 可以使用含水较多的溶剂, 甚至可以使用完全为水的溶剂系统。
( 3 ) 包润滑层: 取双层片置于高效包衣机中, 用润滑层包衣液包 衣, 润滑层包衣增重 (即润滑层重量相对于欢层片片芯重量的百分比) 控制在 0.5% ~ 6%以内。 包衣机的进风温度控制在 40~65 °C之间。
( 4 ) 制备控释层包衣液: 取醋酸纤维素加入到丙酮中, 浸泡、 4觉 拌使溶解, 制成含醋酸纤维素 1% ~ 6% ( w/w )的溶液,加入致孔剂、 增 塑剂, 混合均匀。 其中致孔剂选自聚乙二醇、 聚维酮 (PVP )、 乳糖、 蔗糖、 甘露醇、 山梨醇。 增塑剂选自癸二酸二丁酯、 邻苯二甲酸酯、 柠檬酸三乙酯。
( 5 ) 包控释层: 取包好润滑层的双层片置于高效包衣机中, 用控 释层包衣液包衣, 至控释层增重 (即控释层重量相对于双层片片芯重 量的百分比) 为 18% ~ 24% , 包衣机的进风温度控制在 15~35 °C之间。
( 6 )控释层老化: 取包好控释层的双层片置于干燥设备中干燥, 干燥温度控制在 35 °C ~60 °C之间, 干燥至丙酮的残留量在 0.05%以下。
( 7 )打孔: 取老化好的控释片在含药层一侧打孔, 可以采用激光 打孔、 机械转孔; 孔径控制在 0,4 ~ 1.2mm之间, 可以打一个孔或两个 孔。
( 8 ) 包薄膜衣: 可以选择在打孔的双层渗透泵控释片的外面用常 规的片剂包衣技术包薄膜衣。
本发明的双层渗透泵控释片在传统双层渗透泵控释片的基础上增 加了润滑层, 润滑层由易于水化的材料构成, 润滑层水化后形成具有 润滑作用的凝胶膜, 具有良好的润滑作用。 当推进层吸收水分膨胀, 推动药物层向上移动时, 由于润滑层的润滑作用, 药物层可以整体移 动, 不会产生死角, 最终药物层被完全推出, 药物释放完全。 润滑层 由高取代羟丙基纤维素或低粘度羟丙基甲基纤维素构成, 可以采用常 规的包衣方法对整个双层片片芯包衣制备润滑层, 工艺简单, 易于操 作, 但药物的释放效果大大改善, 同时不影响控释层的包衣工艺过^ , 用最简单的方法解决了大问题。
在优选的实施方案中, 本发明的双层渗透泵控释片为硝苯地平双 层渗透泵控释片, 所述双层片片芯中的药物为硝苯地平。 附图说明
图 1是本发明具有润滑层结构的双层渗透泵控释片的结构示意图 其中, 1-药物层; 2-推进层; 3-润滑层; 4-控释层; 5-释药孔。 图 2是实施例 1的释放效果曲线图
图 3是润滑层的用量对释放的影响
图 4是控释膜增重对释放的影响
图 5润滑层溶剂对释放的影响 实施例
本发明用下面的实施例进行举例说明。 应当理解, 这些实施例仅 是对本发明的举例说明, 而不是限制本发明的范围。
实施例 1 具有润滑层结构的硝苯地平渗透泵控释片。 制备方法如下。
1.硝苯地平原料微粉化: 取硝苯地平原料进行微粉化处理,得粒径 为 ΙΟμιη以下的微粉化原料药备用;
2.硝苯地平固体微粉溶液的制备:
取硝苯地平: 聚维酮 Κ30: 水 = 6: 12: 82 ( w/w ) 混合, 用高速 分散机使其形成稳定均一的水分散体混悬液, 对混悬液喷雾干燥, 制 成硝苯地平固体微粉溶液, 在 40 ~ 50°C干燥, 备用;
3.含药层物料制粒:
含药层配方:
硝苯地平 30.0g
聚维酮 K30 60.0g
聚氧化乙烯 40.0g
羟丙基甲基纤维素 20.0g
硬脂酸镁 l .Og
微粉硅胶 0.75g
1000片
1) 取含药层配方物料中的硝苯地平-聚维酮固体微粉溶液、 聚 化乙烯、 羟丙基甲基纤维素进行干法制粒;
2) 混合: 取制得的颗粒外加微粉硅胶、 硬脂酸镁进行总混, 混合 均匀后备用;
4.推进层物料混合:
推进层配方:
聚氧化乙烯 48.0g
羟丙基甲基纤维素 24.0g
氯化钠 5.0g
氧化铁红 2.0g
硬脂酸镁 O g
1000片
取聚氧化乙烯、 羟丙基甲基纤维素、 氯化钠、 氧化铁紅、 硬脂酸 镁进行总混, 混合均勾后备用;
5.压双层片:取混合均勾的含药层颗粒及推进层物料, 釆用 8.5mm 浅凹冲压制双层片, 片芯备用; 6.制备润滑层包衣液:
润滑层配方
高取代羟丙基纤维素 5 %
乙醇 95 %.
取羟丙基纤维素 5g, 加入 95g乙醇, 搅拌使溶解, 备用;
7.包润滑层:
取压制好的双层片在高效包衣机上包润滑层, 包衣过程控制片床 温度为 45±2°C , 润滑层的增重为 1%;
8.制备控译膜包衣液:
控释层配方:
醋酸纤维素 3.20 %
聚乙二醇 1500 0.48 %
癸二酸二丁酯 0.32 %
丙酮 96.0 %
在丙酮中依次加入醋酸纤维素、 聚乙二醇 1500、 癸二酸二丁酯, 搅拌使分散, 待其固形物全部溶胀后继续搅拌使溶解, 备用;
9.包控释层: 取包完隔离衣的片料在高效包衣机上包制控释膜, 包 衣过程不需对料床加热,控制包衣增重按双层片片芯计为 21 % ( w/w );
10. 控释层老化: ' 取包完控释层的片料放置于 40 ~ 45 °C烘箱中, 老化 16小时。
11. 激光打孔: 取出老化的片剂, 利用激光打孔机在含药层中央打 制释药孔, 孔径为 700μιη。
制得的具有润滑层结构的硝苯地平渗透泵控释片结构如图 1所示, 由含药层 1 和推进层 2组成双层片芯, 在双层片芯外依次是润滑层 3 和控释层 4, 在控释片的含药层一侧上有释药孔 5。
实施例 1的释放效果:
照中国药典规定释放度测定第一法, 采用溶出度第二法装置测定, 释放介质为 1%十二烷基硫酸纳的磷酸盐——柠檬酸緩沖液(ρΗ = 6,8 ) 600ml , 转速为 100转 /分钟, HPLC法测定释放度, 色谱条件为: C18 为固定相, 流动相为: 乙腈-甲醇-水( 20:30:50 ) 。 测定的释放, 结 果 24小时的释放度高于 90%, 符合中国药典关于緩控释制剂的一般规 定。 释放曲线如图 2。 时间 (h ) 0 4 8 12 16 24 释放度 0.0% 17.3% 40.1% 62.3% 75.8% 96.0% 实施例 o o 2 润滑层的用量对释放的影响
按照与实施例 1 相同的材料、 用量和操作制备硝苯地平渗透泵控 释片, 不同之处在于润滑层的增重分别为 0.5%和 6% , 评价润滑层用量 对释放的影响, 释放结果符合中国药典关于緩控释制剂的一般规定,
24小时的释放度大于 90%。 测定释放曲线如图 3。
时间 ( h) 0 4 8 12 16 24 增重 0.5% 0,0% 17.8% 40.1% 60.2% 73.6% 93,3% 增重 6% 0.0% 18.3% 44.1% 64.7% 78.3% 95.7% 结论: 在 0.5% - 6%的润滑层增重范围内 , 润滑层均可以有效发挥 润滑作用。 实施例 3 控释膜增重对释放的影响
按照与实施例 1 相同的材料、 用量和操作制备硝苯地平渗透泵控 释片, 不同之处在于控释膜包衣增重分别为 18%和 24%的控释片, 释 放符合中国药典关于緩控释制剂的一般规定, 24小时释放度大于 90%。 测定结果如下。 释放曲线如图 4。
时间(h ) 0 4 8 12 16 24
23.3% 47.8% 69.7% 81.8% 100.3%
17.8% 40.1% 60.2% 73.6% 93.3%
结论: 控释膜的包衣增重在 18% ~ 24%的范围内,样品均具有良好 的释放度, 24小时的释放在增重 24%时可以达到 90%以上, 符合中国 药典的规定。 实施例 4 润滑层溶剂对释放的影响
按照实施例 1 的方法制备双层片, 按照下面的配方配制两种不同 溶剂的润滑层包衣液。
润滑层 1配方:
羟丙基曱基纤维素 5 %
τ - 95 % 配制方法: 取羟丙基甲基纤维素 5g, 加入 95g水中, 搅拌使溶解, 备用;
润滑层 2配方:
羟丙基甲基纤维素 5g
75g
配制方法: 取羟丙基甲基纤维素 5g, 加入 75g乙醇中, 搅拌使溶 解, 备用;
包润滑层: 取压制好的双层片分两次置于高效包衣机中, 分次包 衣。 笫一次包润滑层 1 , 第二次包润滑层 2 , 包衣过程控制片床温度为 45±2 °C , 润滑层的增重为 2%左右;
按照实施例 1的制备方法进行后续操作。控释层增重分别为 21.3% 和 22.1%, 按照实施例 1的方法测定释放度, 结果两种不同润滑层溶剂 制备的硝苯地平渗透泵控释片的释放均符合中国药典关于緩控释制剂 的一般规定, 24小时的释放度大于 90%。 测定结果如下。 释放曲线如 图 5。
时间(h ) 4 8 12 16 24
水 20.5% 44.0% 66.4% 72. 1% 94.3%
乙醇 18.7% 43.4% 64.1% 70.6% 91.5%
结论: 采用水或乙醇为润滑层包衣液的溶剂均可以制备出平稳释 放的渗透泵控释片, 两者的释放度没有显著差异。

Claims

权 利 要 求
1、 一种双层渗透泵控释片, 所述双层渗透泵控释片包括含有药物 的双层片片芯、 片芯外的控释层和控释层上的释药孔, 其特征在于, 在片芯和控释层之间具有润滑层结构。
2、 根据权利要求 1所述的双层渗透泵控释片, 其特征在于, 其中 所述润滑层的材料选自高取代羟丙基纤维素或低粘度羟丙基甲基纤维 素。
3、 根据权利要求 2所述的双层渗透泵控释片, 其特征在于, 其中 所述高取代羟丙基纤维素的粘度为 2.4 ~ 120mPa's,优选 12~ 80mPa-s。
4、 根据权利要求 2所述的汉层渗透泵控释片, 其特征在于, 其中 所述低粘度羟丙基甲基纤维素的粘度为 5 ~ 100mPa,s, 优选 5 ~ 50mPa's。
5、 根据权利要求 1-4任一项所述的双层渗透泵控释片, 其特征在 于, 所述含有药物的双层片片芯由含药层和推进层組成。
6、 根据权利要求 1 -5 任一项所述的双层渗透泵控释片, 其特征 在于, 所述润滑层的重量是双层片片芯重量的 0.5% ~6%。
7、 根据权利要求 1 -6 任一项所述的双层渗透泵控释片, 其特征 在于, 所述控释层的重量是双层'片片芯重量的 18%~24%。
8、 根据权利要求 1 -7 任一项所述的双层渗透泵控释片, 其特征 在于, 所述控释层的材料是醋酸纤维素。
9、 根据权利要求 1 - 8 任一项所述的双层渗透泵控释片, 其特征 在于, 所述控释片的释药孔的直径是 0.4~1.2mm。
10、 根据权利要求 1 - 13 任一项所述的双层渗透泵控释片, 其中 所述双层渗透泵控释片为硝苯地平双层渗透泵控释片, 所述双层片片 芯中的药物为硝苯地平。
11、 一种制备权利要求 1 - 10 任一项所述的双层渗透泵控释片的 方法, 所述方法包括: 将药物与辅料制成含有药物的双层片片芯, 在 片芯外先包裹一层润滑层, 再在润滑层的外面包控释层, 然后在含药 层一侧的控释层上打孔, 制成双层渗透泵控释片。
12、 根据权利要求 11所述的双层渗透泵控释片的制备方法, 其特 征在于, 所述方法包括以下步骤: ( 1 )制备含有药物的双层片芯:取含药层的物料和推进层的物朴, 用双层压片机制成双层片芯;
(2)制备润滑层包衣液: 取润滑层材料适量加入到水或乙醇或任 意比例的水一乙醇溶液中, 浸泡, 搅拌使溶解; 润滑层材料选自高取 代羟丙基纤维素或低粘度羟丙基甲基纤维素;
(3 ) 包润滑层: 取双层片置于高效包衣机中, 用润滑层包衣液包 衣;
(4) 制备控释层包衣液: 取醋酸纤维素加入到丙酮中, 浸泡、 搅 拌使溶解, 制成含醋酸纤维素 1%~6% (W/W)的溶液,加入致孔剂、 增 塑剂, 混合均匀;
(5 ) 包控释层: 取包好润滑层的双层片置于高效包衣机中, 用控 释层包衣液包衣;
(6) 控释层老化: 取包好控释层的双层片置于干燥设备中干燥,.; 干燥温度控制在 35 Ό〜60 °C之间, 干燥至丙酮的残留量在 0.05%以下。
(7) 打孔: 取老化好的控释片在含药层一侧的控释层上打孔。
13、 根据权利要求 12所述的双层渗透泵控释片的制备方法, 其特 征在于, 所述方法还包括步骤 (8) : 包薄膜衣: 在打孔的双层渗透泵 控释片的外面用常规的片剂包衣方法包薄膜衣。
14、 根据权利要求 11 - 13任一项所述的双层渗透泵控释片的制备 方法, 其中所述默层渗透泵控释片为硝苯地平双层渗透泵控释片, 所 述双层片片芯中药物为硝苯地平。
PCT/CN2009/001473 2008-12-16 2009-12-16 具有润滑层结构的双层渗透泵控释片及其制备方法 WO2010069141A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN2009801509213A CN102264356A (zh) 2008-12-16 2009-12-16 具有润滑层结构的双层渗透泵控释片及其制备方法
JP2011541060A JP2012512187A (ja) 2008-12-16 2009-12-16 潤滑層構造を有する二層浸透圧ポンプ制御放出錠剤及びその調製方法
US13/140,288 US20120015028A1 (en) 2008-12-16 2009-12-16 Controlled-Released Osmotic Pump Tablet with Lubricating Layer and the Preparation Thereof
EP09832823.0A EP2380562A4 (en) 2008-12-16 2009-12-16 OSMOTIC PUMP TABLET WITH CONTROLLED RELEASE AND SLIP LAYER AND ITS MANUFACTURE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200810239714.2 2008-12-16
CN2008102397142A CN101703488B (zh) 2008-12-16 2008-12-16 具有润滑层结构的双层渗透泵控释片及其制备方法

Publications (1)

Publication Number Publication Date
WO2010069141A1 true WO2010069141A1 (zh) 2010-06-24

Family

ID=42268273

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2009/001473 WO2010069141A1 (zh) 2008-12-16 2009-12-16 具有润滑层结构的双层渗透泵控释片及其制备方法

Country Status (5)

Country Link
US (1) US20120015028A1 (zh)
EP (1) EP2380562A4 (zh)
JP (1) JP2012512187A (zh)
CN (2) CN101703488B (zh)
WO (1) WO2010069141A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520111A (ja) * 2011-06-06 2014-08-21 オーク・クレスト・インスティテュート・オブ・サイエンス ウィッキング放出ウィンドウを利用した薬剤デリバリーデバイス
CN115383331A (zh) * 2022-09-22 2022-11-25 上海工程技术大学 控释片激光打孔、高精度红外检测装置

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101856337B (zh) * 2010-05-28 2012-10-03 中国科学院上海药物研究所 一种渗透控释药物传递系统及其制备方法
CN102293760B (zh) * 2011-03-04 2015-03-18 上海医药集团股份有限公司 一种单硝酸异山梨酯择时控释制剂及其制备方法
JP6296371B2 (ja) * 2013-12-23 2018-03-20 ウェン、シャオガンWEN, Xiaoguang 二層錠剤の調製方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1931167A (zh) * 2006-06-28 2007-03-21 广州贝氏药业有限公司 非洛地平双层渗透泵控释药物组合物
US20070166381A1 (en) * 2006-01-06 2007-07-19 Iran Reyes Osmotic dosage form with controlled release and fast release aspects
CN101128190A (zh) * 2005-02-11 2008-02-20 西梯茜生命工学股份有限公司 含盐酸坦索罗辛的控释制剂
CN101167700A (zh) * 2006-10-24 2008-04-30 北京红林制药有限公司 硝苯地平控释片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
WO2000025790A1 (en) * 1998-11-02 2000-05-11 Alza Corporation Controlled delivery of antidepressants
RU2246295C2 (ru) * 1998-11-02 2005-02-20 Элзэ Копэрейшн Лекарственная форма c постоянной скоростью высвобождения лекарственного вещества, ядро лекарственной формы и способ обеспечения облегченного высвобождения лекарственного вещества из лекарственной формы
AU2004275835B2 (en) * 2003-09-26 2011-06-23 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
CN100574748C (zh) * 2003-12-15 2009-12-30 北京科信必成医药科技发展有限公司 择时释放渗透泵控释片
JP2007181427A (ja) * 2006-01-06 2007-07-19 Sanei Gen Ffi Inc 飲料用起泡剤及び/又は泡安定剤、並びにこれを含有する発泡飲料
CN101095681B (zh) * 2007-07-13 2011-04-20 沈阳药大制剂新技术有限公司 盐酸阿夫唑嗪渗透泵型控释制剂及其制备方法
CN101259113B (zh) * 2008-04-21 2013-02-13 沈阳药科大学 依托度酸渗透泵型控释制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101128190A (zh) * 2005-02-11 2008-02-20 西梯茜生命工学股份有限公司 含盐酸坦索罗辛的控释制剂
US20070166381A1 (en) * 2006-01-06 2007-07-19 Iran Reyes Osmotic dosage form with controlled release and fast release aspects
CN1931167A (zh) * 2006-06-28 2007-03-21 广州贝氏药业有限公司 非洛地平双层渗透泵控释药物组合物
CN101167700A (zh) * 2006-10-24 2008-04-30 北京红林制药有限公司 硝苯地平控释片及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2380562A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014520111A (ja) * 2011-06-06 2014-08-21 オーク・クレスト・インスティテュート・オブ・サイエンス ウィッキング放出ウィンドウを利用した薬剤デリバリーデバイス
JP2017101035A (ja) * 2011-06-06 2017-06-08 オーク・クレスト・インスティテュート・オブ・サイエンスOak Crest Institute Of Science ウィッキング放出ウィンドウを利用した薬剤デリバリーデバイス
JP2018048198A (ja) * 2011-06-06 2018-03-29 オーク・クレスト・インスティテュート・オブ・サイエンスOak Crest Institute Of Science ウィッキング放出ウィンドウを利用した薬剤デリバリーデバイス
US9937335B2 (en) 2011-06-06 2018-04-10 Oak Crest Institute Of Science Drug delivery device employing wicking release window
KR102059698B1 (ko) 2011-06-06 2019-12-26 오크 크레스트 인스티튜트 오브 사이언스 심지 방출창을 도입한 약물 전달 장치
CN115383331A (zh) * 2022-09-22 2022-11-25 上海工程技术大学 控释片激光打孔、高精度红外检测装置

Also Published As

Publication number Publication date
CN101703488A (zh) 2010-05-12
CN101703488B (zh) 2013-02-20
EP2380562A4 (en) 2013-12-11
US20120015028A1 (en) 2012-01-19
CN102264356A (zh) 2011-11-30
JP2012512187A (ja) 2012-05-31
EP2380562A1 (en) 2011-10-26

Similar Documents

Publication Publication Date Title
TW550090B (en) Stable oral pharmaceutical dosage forms for acid-unstable drug
JP5167345B2 (ja) 薬剤を加速放出する腸溶コーティングを含む固体剤形
JP4963767B2 (ja) 制御放出性製剤の製法
Wesseling et al. Drug release from beads coated with an aqueous colloidal ethylcellulose dispersion, Aquacoat®, or an organic ethylcellulose solution
EP2510923B1 (en) Coating composition, solid preparation coated therewith, and method for preparing solid preparation
WO2006026504A2 (en) Mucoadhesive oral formulations of high permeability, high solubility drugs
WO2009059510A1 (fr) Composition pharmaceutique solide sensible au ph pour formulation orale et procede de preparation associe
US8753682B2 (en) Dual release oral tablet compositions of dexlansoprazole
WO2010069141A1 (zh) 具有润滑层结构的双层渗透泵控释片及其制备方法
WO2015154655A1 (zh) 一种控释片
JP2007332101A (ja) 腸溶性顆粒剤及びその製造方法
CN103784414A (zh) 一种埃索美拉唑肠溶片及其制备方法
KR20070094627A (ko) 비점착제와 함께 미분화된 장용 중합체를 포함하는 장용 막피복 조성물
US9114085B2 (en) Modified release pharmaceutical compositions of dexlansoprazole
US20050106252A1 (en) Combination of polyvinyl acetate with water-insoluble, acid-insoluble, or alkali-insoluble polymers used for the production of film coatings with highly controlled release and high stability
JP2012512187A5 (zh)
Ha et al. Preparation and evaluation of sustained-release doxazosin mesylate pellets
ITFI20070253A1 (it) Formulazioni farmaceutiche per la somministrazione di ipp.
JP5070618B2 (ja) 腸溶性顆粒剤及びその製造方法
JPH0791184B2 (ja) 放出制御型製剤およびその製法
CN104758266B (zh) 一种非洛地平缓释片及其制备工艺
JP2016128391A (ja) フィルムコーティング液並びに経口固形製剤及びその製造方法
WO2024022382A1 (zh) 渗透泵控释制剂、渗透泵控释组合物、制备方法和应用
JP5919173B2 (ja) 徐放性塩酸アンブロキソール口腔内崩壊錠
JP5819800B2 (ja) 高粘度ヒプロメロースを分散したコーティング液及び固形製剤の製造方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980150921.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09832823

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011541060

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009832823

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13140288

Country of ref document: US